Overview Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir Status: Completed Trial end date: 2019-09-25 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of a 90-day intravaginal ring (IVR) containing tenofovir (TFV). Phase: Phase 1 Details Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Treatments: Tenofovir